Humacyte, Inc.
HUMA
$1.42
$0.031.80%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 28.97% | -41.66% | 53.50% | -196.22% | 286.91% |
| Total Depreciation and Amortization | 0.11% | -4.13% | 0.27% | 1.53% | 1.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -258.57% | 225.76% | -138.38% | 117.97% | -1,113.75% |
| Change in Net Operating Assets | 84.30% | -101.70% | -194.78% | 85.38% | -282.41% |
| Cash from Operations | 3.90% | -9.29% | 9.50% | 7.65% | -7.62% |
| Capital Expenditure | -348.72% | 20.41% | 91.37% | -149.12% | -261.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -348.72% | 20.41% | 91.37% | -149.12% | -261.90% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 13.59% | -2.20% | -5.82% | -2.08% |
| Issuance of Common Stock | -58.79% | 813.10% | 91.68% | -93.18% | -9.99% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 22.96% | -14,619.12% | -- | -- |
| Cash from Financing | -59.21% | 228.21% | -2,158.68% | -95.37% | -8.37% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -106.31% | 145.24% | -176.22% | -238.55% | -26.50% |